The cancer drug eribulin has been originally developed from sea sponges. It could give women with advanced triple negative breast cancer an average of 5 extra months to live. This was revealed in a research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool today (Monday). Researchers led by Professor Chris Twelves, based at the University of Leeds and Leeds Teaching Hospitals NHS Trust, looked at two major clinical trials ...Monday, 3 November 2014
Increasing Breast Cancer Survival by 5 Extra Months
The cancer drug eribulin has been originally developed from sea sponges. It could give women with advanced triple negative breast cancer an average of 5 extra months to live. This was revealed in a research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool today (Monday). Researchers led by Professor Chris Twelves, based at the University of Leeds and Leeds Teaching Hospitals NHS Trust, looked at two major clinical trials ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment